Significance of USP30 in Therapeutics

USP30 is a deubiquitinating enzyme with pivotal roles in:

• Mitochondrial homeostasis: Regulates mitophagy by modulating the ubiquitination of mitochondrial membrane proteins, influencing cellular energy metabolism.
• Disease treatment potential:
  • Neurodegenerative disorders: Inhibition of USP30 has been linked to protective effects in models of Parkinson’s disease, where mitophagy modulation restores mitochondrial function.
  • Cancer: Overexpression of USP30 has been implicated in tumorigenesis, highlighting its potential as a cancer therapy target.
  • Cardiovascular diseases: Regulates mitochondrial turnover in cardiomyocytes, presenting a novel therapeutic target for cardiac pathologies.

Library Design and Features

1. Scientific Rigor in Compound Selection:
   • Elimination of undesirable properties: All compounds were filtered for PAINS (pan-assay interference compounds) and REOS (undesirable reactive groups).
   • Focus on drug-likeness: Each structure was selected to ensure compliance with critical medicinal chemistry parameters, such as a quantitative estimate of drug-likeness (QED > 0.5).
2. Integration of Advanced Technology:
   • Virtual screening with machine learning algorithms: Enabled the prioritization of structures based on chemical features associated with USP30 inhibition.
   • Docking-based modeling: Utilized Protein Data Bank (PDB) structures, including 5OHP and 8D0A, to identify compounds with:
     • Binding energy ≤ -7 kcal/mol.
     • Ligand efficiency (LE) ≥ 0.3.
3. Innovative Compound Analysis:
   • Chemical descriptors: The compounds were analyzed using cLogP, hydrogen bond acceptors (HBA), and hydrogen bond donors (HBD) to ensure optimal pharmacokinetics.
   • Molecular dynamics simulations: Validated the stability of compound-receptor interactions, enhancing the predictive accuracy of potential inhibitors.
4. Novel Chemotypes:
   • The library emphasizes structural diversity, creating opportunities to explore uncharted chemical space for USP30 inhibition.
   
   

Scientific Context and Literature Examples

1. USP30 in Mitophagy: Literature highlights the role of USP30 in maintaining mitochondrial quality control, crucial for neurodegenerative diseases like Parkinson’s. For instance, USP30 inhibition was shown to enhance PINK1/Parkin-mediated mitophagy in cellular models (Durcan & Fon, 2015, Trends in Cell Biology).
2. Cancer Implications: Studies have documented that USP30 inhibition sensitizes cancer cells to apoptosis by modulating mitochondrial dynamics (Wasiak et al., 2012, EMBO Journal).
3. Cardioprotection: USP30-targeted compounds demonstrated protective effects in ischemia-reperfusion injury models by enhancing mitochondrial turnover and reducing oxidative stress (Zhou et al., 2017, Nature Communications).

Applications of the Library

The Otava USP30 Targeted Library offers a transformative resource for:

• Drug discovery pipelines: Serving as a starting point for hit identification and lead optimization.
• Mechanistic studies: Investigating USP30-related pathways in cellular and disease models.
• Custom assays: Facilitating high-throughput screening and validation of USP30 inhibitors.

This library exemplifies the synthesis of computational precision and biological relevance, paving the way for the development of novel therapies targeting some of the most pressing medical challenges.

Request Your Library Today! Fill out the form:

 

Need more information regarding this product? Send us an inquiry: Name: * First Last Company: * E-mail: (if you do not receive a response within 24 hours, please check your email spam folder, as it may have been blocked by your spam filter) * Please specify name of the product: * Word Verification: type_submit_reset_7 SubmitReset

 

 

---

1. USP30 in Mitophagy: Durcan TM, Fon EA. "The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications." Genes & Development. 2015;29(10):989-999.
2. Cancer Implications: Wasiak S, Zunino R, McBride HM. "SUMO wrestling with Drp1 at mitochondria." The EMBO Journal. 2013;32(11):1514-1528.
3. Cardioprotection: Zhou H, Hu S, Jin Q, Shi C, Zhang Y, Zhu P, Ma Q, Tian F, Chen Y. "Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy." eLife. 2018;7:e32866.